A Single Centre, double blind, placebo controlled, randomised trial to evaluate the efficacy and safety of Simvastatin in the treatment of Psoriasis. - Statin & Psoriasis

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2005-000989-39-GB

Enrollment

Registered

2005-06-13

Start date

2005-09-23

Completion date

Unknown

Last updated

2019-12-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Psoriasis

Interventions

Trade Name: Simvador 40mg tablets Product Name: Simvastatin Pharmaceutical Form: Tablet INN or Proposed INN: Simvastatin Concentration unit: mg milligram(s) Concentration type: equal Concentration num

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Written informed consent Clinical diagnosis of chronic stable plaque psoriasis (minimum 5% body surface area) for 6 months Age 18-65 Male or Female Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: A concurrent diagnosis of pustular, guttate or erythrodermic psoriasis. Patient who have a history of Coronary Artery Disease. Patients who are currently taking warfarin, diltiazem, amiodarone or verapramil for any indication. Treatment with any other systemic psoriasis therapies where the dose has changed 2 months prior to the entry of the study. Females who are pregnant, breastfeeding, or whom are planning a pregnancy.

Design outcomes

Primary

Measure	Time frame
Main Objective: The objectives of the trial are to compare the efficacy of simvastatin in the treatment of common plaque psoriasis. ;Secondary Objective: The objectives of the trial are to compare the safety of simvastatin in the treatment of common plaque psoriasis.;Primary end point(s): The primary end point is to compare the safety and efficacy of simvastatin in the treatment of common plaque psoriasis using validated scoring systems.	—

Measure

Time frame

Main Objective: The objectives of the trial are to compare the efficacy of simvastatin in the treatment of common plaque psoriasis. ;Secondary Objective: The objectives of the trial are to compare the safety of simvastatin in the treatment of common plaque psoriasis.;Primary end point(s): The primary end point is to compare the safety and efficacy of simvastatin in the treatment of common plaque psoriasis using validated scoring systems.

—

Countries

United Kingdom

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026